NEWARK, Del, June 29, 2023 (GLOBE NEWSWIRE) -- As per Future Market Insights’ latest industry analysis, expanding at a CAGR of 5.2%, the global Proton Pump Inhibitors Market is projected to increase from a valuation of US$ 2.8 Billion in 2022 to US$ 4.9 Billion by 2033.
The market for Proton Pump Inhibitors (PPIs) is being driven by the increasing prevalence of gastrointestinal disorders. Conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Helicobacter pylori infections are becoming more common worldwide. PPIs are widely prescribed to manage and treat these disorders effectively. As the number of individuals affected by gastrointestinal issues continues to rise, the demand for PPIs as a primary treatment option is also increasing. This trend underscores the importance of PPIs in addressing the growing burden of gastrointestinal disorders and highlights the significant role they play in improving patient outcomes and quality of life.
For Details about Vendors and their Offerings – request your Sample Report here @ https://www.futuremarketinsights.com/reports/sample/rep-gb-17480
Strong research and development (R&D) activities are a key driver of the Proton Pump Inhibitor (PPI) market. Ongoing R&D efforts in the field of gastroenterology and drug development have led to the introduction of new and improved PPI formulations. These innovations, including novel drug delivery systems and enhanced efficacy profiles, attract healthcare professionals and patients alike. The continuous pursuit of advancements in PPI medications not only improves treatment options but also addresses the evolving needs of patients with gastrointestinal disorders. Consequently, the market for PPIs is propelled forward by the commitment to R&D, fostering innovation, and ultimately providing better therapeutic solutions for patients worldwide.
Top Highlights by FMI’s Analysis:
- Omeprazole dominates the Proton Pump Inhibitors (PPIs) market, holding a significant market share of 28.5% in 2022. This leading position is driven by various factors, including its widespread availability, proven efficacy, and comparatively lower cost compared to other PPI drugs.
- The oral route of administration holds the leading position with a market share of 66.3% in 2022. Oral administration is the preferred method for delivering Proton Pump Inhibitors due to its convenience, ease of use, and high patient acceptance. It allows for effective systemic delivery of the medication, contributing to its dominant position in the market.
- Capsules are the leading dosage form with a market share of 39.2% in the global Proton Pump Inhibitors market in 2022. Capsules offer advantages such as easy swallowing, accurate dosing, and protection of the medication from degradation. They are preferred by healthcare professionals and patients for their convenience and effectiveness in delivering Proton Pump Inhibitors for treatment.
- Generics held a 74.3% market value share in 2022 in the global Proton Pump Inhibitors market based on prescription type. Generic Proton Pump Inhibitors have gained prominence due to their cost-effectiveness, comparable efficacy, and availability as alternatives to brand-name medications.
- North America leads the global market in terms of region accounting for 38.8% market share in 2022. This is attributed to factors such as the high prevalence of gastrointestinal disorders, well-established healthcare infrastructure, robust research and development activities, and strong market presence of key pharmaceutical companies.
“The demand for photon pump inhibitors is increasing due to the growing prevalence of gastroesophageal reflux disease (GERD) and the need for effective treatment options,” - says an analyst at Future Market Insights (FMI).
Ask for more details About This Market Along With a Detailed Analysis of the Top Regions @ https://www.futuremarketinsights.com/ask-question/rep-gb-17480
Competitive Landscape:
The market players active within this industry space are undertaking launch of new product to continue maintaining their market share in the global market.
- On April 2022, Daewon Pharmaceutical launched Escorten, its inaugural proton-pump inhibitor (PPI) treatment, utilizing 10mg of esomeprazole magnesium trihydrate, effectively addressing gastric mucosal lesions in acute and chronic gastritis in Korea.
- On March 25, 2021, Xiromed LLC, a generic division of Insud Pharmaceuticals, launched Omeprazole delayed-release capsules, 20mg, as a cost-effective alternative to Prilosec®. CEO Narasimhan Mani expressed their commitment to expanding the product portfolio.
Major Players are:
AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Eisai Inc., GlaxoSmithKline PLC, Pfizer Inc., Takeda Pharmaceuticals, Sanofi SA, Perrigo Company PLC, Dr. Reddy's Laboratories, Redhill Pharma Limited, Cipla Limited
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the Proton Pump Inhibitors market in its latest study, presenting a historical demand assessment of 2017 to 2022 and projections for 2023 to 2033. The global Proton Pump Inhibitors market is segmented in detail to cover every market aspect and present a complete market intelligence approach to the reader.
The research study is based on the Proton Pump Inhibitors market by drug type (omeprazole, pantoprazole, rabeprazole, dexlansoprazole, lansoprazole, esomeprazole, and others), by route of administration (oral, and injectable), by dosage form (tablet, capsules, injection, and others), by prescription type (branded, and generics), by indication (gastroesophageal reflux disease, heartburn, peptic ulcer, and others), by distribution channel (retail pharmacies, hospital pharmacies, drug stores, and specialty clinics), and across 7 regions of the world.
Key Segmentation:
By Drug Type:
- Esomeprazole
- Omeprazole
- Dexlansoprazole
- Pantoprazole
- Rabeprazole
- Lansoprazole
- Others
By Route of Administration:
- Oral
- Injectable
By Dosage Form:
- Tablet
- Capsules
- Injection
- Others
By Prescription:
- Branded
- Generics
By Indication:
- Gastroesophageal Reflux Disease
- Heartburn
- Peptic ulcers
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Speciality Clinics
Request Methodology @ https://www.futuremarketinsights.com/request-report-methodology/rep-gb-17480
Table of Content (ToC):
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value-Added Insights
4.1. Product Adoption and Usage Analysis-By Region
4.2. Disease Epidemiology-By Key Indication
4.3. Regulatory Landscape-by Country
4.4. Reimbursement Outlook
4.5. New Drug Launches & Approvals
4.6. Pipeline Assessment
4.7. Value Chain Analysis
4.8. Regional PESTLE Analysis
4.9. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Rise in Healthcare Spending
5.1.2. Global Pharmaceutical Market Outlook
5.1.3. Global Lifescience Market Outlook
5.1.4. Global Gastroesophageal Reflux Disease Therapeutics Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising prevalence of gastroesophageal reflux disease (GERD)
5.2.2. Increasing aging population
5.2.3. Growing incidence of Helicobacter pylori infections
5.2.4. Increasing adoption of self-medication
5.2.5. Technological advancements in drug delivery systems
5.2.6. Increasing awareness and Patient education
5.2.7. Expansion of the pharmaceutical industry in emerging markets
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017–2022 and Forecast, 2023 to 2033
6.1. Historical Market Value (US$ Million) Analysis, 2017–2022
6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
Buy Now to Gain Access to Detailed Information About Each Segment and Identify Key Trends, Drivers, and Challenges in this Market @ https://www.futuremarketinsights.com/checkout/17480
Have a Look at Related Reports of the Healthcare domain:
Gastroesophageal Reflux Disease Therapeutics Market Size: The global market for GERD therapies, which was estimated at US$ 4.7 Billion in 2022 and it is predicted to have a revenue reduction to US$ 3.4 Billion by 2032, declining at a CAGR of 3%.
Gastroesophageal Reflux Disease (GERD) Devices Market Share: Global sales of gastroesophageal reflux disease (GERD) devices were valued at around US$ 1.12 Billion at the end of 2021. The GERD devices market is projected to register 4.3% CAGR and top a valuation of US$ 1.5 Billion by 2028.
Gastroesophageal Junction Adenocarcinoma Therapeutics Market Demand: The global Gastroesophageal Junction Adenocarcinoma Therapeutics market garnered a market value of US$ 5.55 Billion in 2022 and is expected to accumulate a market value of US$ 34.3 Billion by registering a CAGR of 18% in the forecast period 2023 to 2033.
PARP Inhibitors Market Trends: The global Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors Market is estimated to top US$ 5.51 Billion by 2022. Surging demand for advanced targeted therapy for the treatment of chronic diseases such as cancer is augmenting the growth in the market.
Implantable Drug Infusion Pumps Market Analysis: Implantable drug infusion pumps are surgically implanted under the skin. These pumping devices release medications through a catheter or tube to a specific body part.
Next Generation Infusion Pump Market Growth: The global next generation infusion pump market holds a forecasted share of US$ 5059.7 million in 2022 and is likely to surpass US$ 8509 million by 2032, moving ahead with a CAGR of 4.8% during the forecast period.
Multi-therapy Infusion Pumps Market Insights: The global multi-therapy infusion pumps market size is projected to reach US$ 370.4 million in 2023. Over the next ten years, global multi-therapy infusion pump sales are likely to soar at 6.6% CAGR. By 2033, total market valuation is anticipated to surpass US$ 699.4 million.
Interleukin-6 (IL-6) Inhibitors Market Forecast: The market value is projected to increase from US$ 33.3 Billion in 2023 to US$ 93.3 Billion by 2033.
PD-1/PD-L1 Inhibitors Market Overview: The PD-1/PD-L1 inhibitors market size is projected to be valued at US$ 49.5 billion in 2023 and is expected to reach a valuation of US$ 123.3 billion by 2033.
SGLT2 Inhibitors Treatment Market Outlook: SGLT2 Inhibitors Treatment market is looking forward to grow at a higher rate in the forecast period of 2021-2031. SGLT2 Inhibitors help in reabsorption of glucose from the kidney leading to low blood glucose level.
About Future Market Insights (FMI):
Future Market Insights, Inc. (ESOMAR certified, Stevie Award - recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10 years.
Contact Us:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
